关注肝病患者肌少症

doi:10.3969/j.issn.1672-5069.2017.05.002

Abstract

Wu Jiang， Fan Jiangao.. Sarcopenia:a new focus in liver disease[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(5): 516-519.

[1] Rosenberg IH. Sarcopenia:origins and clinical relevance. J Nutr，1997，127（Suppl 5）:990S-991S.
[2] Sinclair M，Gow PJ，Grossmann M，et al. Review article: sarcopenia in cirrhosis-aetiology，implications and potential therapeutic interventions. Aliment Pharmacol Ther，2016，43（7）:765-777.
[3] Dasarathy S，Merli M. Sarcopenia from mechanism to diagnosis and treatment in liver disease. J Hepatol，2016，65（6）:1232-1244.
[4] Hara N，Iwasa M，Sugimoto R，et al. Sarcopenia and sarcopenic obesity are prognostic factors for overall survival in patients with cirrhosis. Intern Med，2016，55（8）:863-870.
[5] Durand F，Buyse S，Francoz C，et al. Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography. J Hepatol， 2014，60（6）:1151-1157.
[6] Merli M，Giusto M，Lucidi C，et al. Muscle depletion increases the risk of overt and minimal hepatic encephalopathy:results of a prospective study. Metab Brain Dis，2013，28（2）:281-284.
[7] van Vugt JL，Levolger S，de Bruin RW，et al. Systematic review and Meta-analysis of the impact of computed tomography-assessed skeletal muscle mass on outcome in patients awaiting or undergoing liver transplantation. Am J Transplant，2016，16（8）:2277-2292.
[8] Quigley EM，Stanton C，Murphy EF. The gut microbiota and the liver. Pathophysiological and clinical implications. J Hepatol，2013，58（5）:1020-1027.
[9] Dasarathy S. Consilience in sarcopenia of cirrhosis. J Cachexia Sarcopenia Muscle，2012，3（4）:225-237.
[10] Garcia PS，Cabbabe A，Kambadur R，et al. Brief-reports:elevated myostatin levels in patients with liver disease:a potential contributor to skeletal muscle wasting. Anesth Analg，2010，111（3）:707-709.
[11] Tsien C，Davuluri G，Singh D，et al. Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis. Hepatology，2015，61（6）:2018-2029.
[12] Beyer I，Mets T，Bautmans I. Chronic low-grade inflammation and age-related sarcopenia. Curr Opin Clin Nutr Metab Care，2012，15（1）:12-22.
[13] Tovo CV，Fernandes SA，Buss C，et al. Sarcopenia and non-alcoholic fatty liver disease:Is there a relationship A systematic review. World J Hepatol，2017，9（6）:326-332.
[14] Lee YH，Jung KS，Kim SU，et al. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance:Nationwide surveys （KNHANES 2008-2011）. J Hepatol，2015，63（2）:486-493.
[15] Lee YH，Kim SU，Song K，et al. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease:Nationwide surveys （KNHANES 2008-2011）. Hepatology，2016，63（3）:776-786.
[16] Cruz-Jentoft AJ，Baeyens JP，Bauer JM，et al. Sarcopenia: European consensus on definition and diagnosis:Report of the European Working Group on Sarcopenia in Older People. Age Ageing，2010，39（4）:412-423.
[17] Fielding RA，Vellas B，Evans WJ，et al. Sarcopenia:an undiagnosed condition in older adults. Current consensus definition: prevalence，etiology，and consequences. International working group on sarcopenia. J Am Med Dir Assoc，2011，12（4）:249-256.
[18] Chen LK，Liu LK，Woo J，et al. Sarcopenia in Asia:consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc，2014，15（2）:95-101.
[19] 余卫，程晓光，袁凌青. 肌少症的评估方法. 中华骨质疏松和骨矿盐疾病杂志，2016，9（3）:240-246.
[20] Prado CM，Lieffers JR，McCargar LJ，et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts:a population-based study. Lancet Oncol，2008，9（7）:629-635.
[21] Lauretani F，Russo CR，Bandinelli S，et al. Age-associated changes
in skeletal muscles and their effect on mobility:an operational diagnosis of sarcopenia. J Appl Physiol（1985），2003，95（5）:1851-1860.
[22] Tsien C，Shah SN，McCullough AJ，et al. Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent. Eur J Gastroenterol Hepatol，2013，25（1）:85-93.
[23] 中国营养学会老年营养分会. 中国营养学会临床营养分会，中华医学会肠外肠内营养学分会老年营养支持学组. 肌肉衰减综合征营养与运动干预中国专家共识（节录）. 营养学报，2015，37（4）:320-324.
[24] Plauth M，Cabre E，Riggio O，et al. ESPEN Guidelines on Enteral Nutrition:Liver disease. Clin Nutr，2006，25（2）:285-294.
[25] Ney M，Vandermeer B，van Zanten SJ，et al. Meta-analysis:oral or enteral nutritional supplementation in cirrhosis. Aliment Pharmacol Ther，2013，37（7）:672-679.
[26] Tsien CD，McCullough AJ，Dasarathy S. Late evening snack: exploiting a period of anabolic opportunity in cirrhosis. J Gastroenterol Hepatol，2012，27（3）:430-441.
[27] Morihara D，Iwata K，Hanano T，et al. Late-evening snack with branched-chain amino acids improves liver function after radiofrequency ablation for hepatocellular carcinoma. Hepatol Res，2012，42（7）:658-667.
[28] Hickman IJ，Jonsson JR，Prins JB，et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase，fasting insulin，and quality of life. Gut，2004，53（3）:413-419.
[29] Roman E，Torrades MT，Nadal MJ，et al. Randomized pilot study:effects of an exercise programme and leucine supplementation in patients with cirrhosis. Dig Dis Sci，2014，59（8）:1966-1975.
[30] Hayashi F，Matsumoto Y，Momoki C，et al. Physical inactivity and insufficient dietary intake are associated with the frequency of sarcopenia in patients with compensated viral liver cirrhosis. Hepatol Res，2013，43（12）:1264-1275.
[31] 曹海霞，范建高. 肝硬化患者营养评估及营养支持治疗. 实用肝脏病杂志，2014，17（5）:459-462.
[32] 段钟平. 肝病营养问题再关注. 实用肝脏病杂志，2014，17（5）:449-451.

Sarcopenia:a new focus in liver disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Ren Yufei, Chen Xiaoqing, Kong Weizong, et al.. Effect of salvianolic acid B on autophagy in nonalcoholic fatty liver disease cell model in vitro [J]. Journal of Practical Hepatology, 2019, 22(6): 804-807.
[2]	Li Yingyi, Guo Cuifen, Zhang Ruinan, et al.. Correlation of polymorphism of ALDH2 rs671 to morbidity in individuals prone to nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(6): 848-851.
[3]	Ding Wenjin, Fan Jiangao.. Management of complications associated with cholestatic liver disease [J]. Journal of Practical Hepatology, 2019, 22(6): 938-940.
[4]	. [J]. Journal of Practical Hepatology, 2019, 22(5): 624-635.
[5]	Zhang Xu Lei, Yang Qingyu, Han Qiuyu, et al. Short-term efficacy of herbal medicine in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(5): 660-663.
[6]	Lu Lungen. Cholestatic liver diseases：What we know and how to deal with [J]. Journal of Practical Hepatology, 2019, 22(5): 754-757.
[7]	Hong Jia, Wu Xiaoning, You Hong. Standardized diagnosis of cholestatic liver diseases [J]. Journal of Practical Hepatology, 2019, 22(5): 758-760.
[8]	Tang Chengwei. Chronic liver disease and thrombocytopenia：Changes in clinical management concept [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 457-458.
[9]	Yan Xisheng, Li Wei, Wang Jian, et al. Changes of serum cytokines and intestinal flora distribution in patients with alcoholic liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 518-521.
[10]	Zhang Lanhua, Shao Qin, Xia Zhenjuan. Changes of serum 25-(OH) D3 and IL-17 levels are associated with progress of nonalcoholic fatty liver disease in obese children [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 522-525.
[11]	Xie Xiao, Liu Ting, Dong Zhixia, et al. Value of controlled attenuation parameter in diagnosis of individuals with liver steatosis by using Fibrotouch [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 526-529.
[12]	Fu Liang, Wu Dongbing, Ji Xinzun. Application of ARFI quantification in the evaluation of liver injuries in patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 377-380.
[13]	Wang Haifang, Yang Dawei, Jia Bei. Impact of nutrition support and medusa administration on liver function, erythrocyte and platelet parameters in patients with alcoholic liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 381-384.
[14]	Zhu Guangxi，Wen Liangzhi，Chen Dongfeng. Pathogenesis of non-alcoholic fatty liver disease-related hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 453-456.
[15]	Huo Huiqin, Gong Xiaohong, Li Zhenghong. Assessment of right atrial and ventricular functions in patients with nonalcoholic fatty liver disease-induced liver cirrhosis by real-time three-dimensional echocardiography and speckle tracking imaging [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 244-247.